ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM's corporate venturing unit has joined in a $20 million round of financing in the Chinese firm Tianjin Green Bio-Science (TGBS). Proceeds are earmarked for construction of a plant in the Tianjin Economic Development Area. The plant is expected to be China's largest producer of fermentation-derived polyhydroxyalkanoates (PHA). In parallel with the investment, DSM and TGBS will cooperate in creating a new business in biology-based performance materials based on PHA. Construction on the 10,000-metric-ton-per-year plant will start this spring, with production expected in early 2009. Separately, DSM's venturing unit has bought "a significant minority share" in the Dutch company IQ Therapeutics, which develops antibody-based products for biodefense and infectious diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X